← brief for 2026-09-16 · Slowing decline

Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review.

Article No results yet Peer reviewed

Key takeaways

This review compares three weight-loss and diabetes drugs: semaglutide, liraglutide and tirzepatide. It looks at blood sugar, weight, heart outcomes and some kidney outcomes. It sums up earlier studies and adds no new data. Because it is a narrative review and not a pooled analysis, it cannot rank the drugs with strong evidence.

Who did this work

Bawadi H · Abuhijleh H · Nofal M · Zakaria ZZ · Al-Asmakh M

Source

Article · PubMed, the drug frontier · 2026 Sep
https://pubmed.ncbi.nlm.nih.gov/42747132/